Search Within

Andrew L. Laccetti

Formats
  1. Meeting Abstract (21)
  2. Journal Article (5)
  3. Review (1)
Groups
  1. Genitourinary Oncology Service (27)
  2. Solid Tumor Oncology Division (27)
  3. Department of Medicine (17)
  4. Hematologic Malignancies, Division of (9)
  5. Weinberg Fellows (9)
  6. Radiology, Department of (8)

More Groups

People
  1. David Aggen (9)
  2. Deaglan McHugh (8)
  3. Neil Shah (8)
  4. Ritesh Kotecha (8)
  5. Jonathan Rosenberg (7)
  6. Chung-Han Lee (6)

More People

Years
  1. 2025 (4)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (1)
  5. 2021 (3)
  6. 2020 (3)
Publications
  1. Journal of Clinical Oncology (18)
  2. Annals of Oncology (3)
  3. Cancer Medicine (1)
  4. Clinical Nuclear Medicine (1)
  5. ESMO Open (1)
  6. European Urology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (18)
  2. Oxford University Press (3)
  3. Dove Medical Press Ltd (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. European Society for Medical Oncology (1)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib plus nivolumab in patients with non–clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Journal Article

    Fitzgerald, K. N.; Lee, C. H.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y.; Lefkowitz, R. A.; Shah, N. J.; Owens, C. N.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
    Meeting Abstract

    Laccetti, A. L.; Chatta, G.; Kyriakopoulos, C.; Iannotti, N.; Hotte, S. J.; Markowski, M. C.; Pili, R.; Vuky, J.; Zhang, J.; Saad, F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical (131)I-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Laccetti, A. L.; Bodei, L.; O'Donoghue, J. A.; Weber, W. A.; Morris, M. J.
    Clinical Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Meeting Abstract

    Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio)
    Meeting Abstract

    Hahn, A. W.; Slack Tidwell, R.; Thoman, W.; Abdulla, A.; Koutroumpakis, E.; Aparicio, A.; Subudhi, S. K.; Siddiqui, B. A.; Pilié, P. G.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Pachynski, R. K.; Iannotti, N.; Laccetti, A. L.; Carthon, B. C.; Chi, K. N.; Smith, M. R.; Vogelzang, N. J.; Tu, W.; Kwan, E. M.; Wyatt, A. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Laccetti, A. L.; Chatta, G. S.; Iannotti, N.; Kyriakopoulos, C.; Villaluna, K.; Le Moigne, R.; Cesano, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save